Tackling a large challenge for new modes of drug delivery

by Marie Daniels
Tackling a large challenge for new modes of drug delivery
Cancer cell.

New treatments for prostate cancer, multiple sclerosis and cystic fibrosis could be developed following research being carried out into how medicinal 'biologics' can be delivered to diseased cells.

Currently only 15 per cent of protein targets in human can be 'targeted therapeutically', rendering the remaining 85 per cent of proteins out of reach of traditional small drug treatments.

Dr Ishwar Singh, from the School of Pharmacy, University of Lincoln, UK, is now looking to develop a platform technology for tumour-specific delivery of biologics – large molecule drugs based on , proteins and peptides with a potent and highly therapeutic effect.

He said: "Large molecule drugs are just that – too big to pass through to the . The challenge is to find a way to deliver these large molecules to the cells. Cell penetrating peptides (CPPs) are known to facilitate the delivery of therapeutic biologics into target cells. Unfortunately current CPPs are highly toxic, which has prevented their widespread use. The aim of our project is to develop a non-toxic drug delivery method which enables CPPs to selectively pass through cell membranes of cancer cells, delivering the drug to the target site without causing toxicity.

"In the long-term we will be able to use this approach to treat conditions such as Multiple Sclerosis, and even some forms of cancer that are currently resistant to available drugs. We are developing a platform technology which could then be applied to a range of conditions."

Biologics differ from small drug molecules not only in terms of size, but also in how they are made, how they behave, their mode of action in the body and their suitability for certain drug forms.

Small, chemically manufactured molecules are the classic active substances and still make up more than 90 per cent of drugs on the market today. However, therapeutics based on large molecules, such as antibodies, are becoming increasingly important.

Small molecules can be processed into easily ingestible tablets or capsules. When the tablet dissolves in the gastrointestinal tract, the dissolved active substance is absorbed into the bloodstream via the intestinal wall. Small drugs can then reach the site of action in the body because of their tiny size. Their small structure and chemical composition also helps them to penetrate cell membranes.

Large , which are created by biological or synthetic processes, are made up of proteins, nucleic acids, sugars or a complex combination of these substances, or may be living entities such as cells. Delivery of these therapeutics to target sites is therefore a more complex process.

Dr Singh has been awarded a Royal Society Research Grant which will facilitate his research with colleague Dr Driton Vllasaliu for the next year.

add to favorites email to friend print save as pdf

Related Stories

Cholesterol rafts deliver drugs inside cancer cells

Apr 02, 2013

DNA, siRNA and miRNA can reprogram cancer cells – that is, if these nucleic acids could cross through the cell membrane. A University of Colorado Cancer Center study published today in the journal Therapeutic Delivery shows ...

Nanotech drug smugglers

Nov 12, 2013

Tiny capsules of carbon are invisible to the chemical gatekeeper that flushes potentially harmful substances out of our bodies' cells, according to research published in the International Journal of Computational Biology an ...

Recommended for you

Immune checkpoint inhibitors may work in brain cancers

2 hours ago

New evidence that immune checkpoint inhibitors may work in glioblastoma and brain metastases was presented today by Dr Anna Sophie Berghoff at the ESMO Symposium on Immuno-Oncology 2014 in Geneva, Switzerland.

New model of follow up for breast cancer patients

5 hours ago

Public health researchers from the University of Adelaide have evaluated international breast cancer guidelines, finding that there is potential to improve surveillance of breast cancer survivors from both a patient and health ...

Immunotherapy set to revolutionise cancer treatment

7 hours ago

Immunotherapy is set to revolutionise the treatment of cancer, according to ESMO President Professor Rolf A. Stahel. His comments come as the ESMO Symposium on Immuno-Oncology 2014 is about to open in Geneva, Switzerland ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.